Bio-Path Inc. (BPTH)
| Bid | 0.2 |
| Market Cap | 980.54K |
| Revenue (ttm) | 523.83K |
| Net Income (ttm) | -20.1M |
| EPS (ttm) | -8.34 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -0.54 |
| Analyst | Buy |
| Ask | 0.21 |
| Volume | 32,945 |
| Avg. Volume (20D) | 2,566,406 |
| Open | 0.16 |
| Previous Close | 0.16 |
| Day's Range | 0.16 - 0.17 |
| 52-Week Range | 0.12 - 7.67 |
| Beta | 0.13 |
About BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials f...
Analyst Forecast
According to 1 analyst ratings, the average rating for BPTH stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 11664.71% from the latest price.
2 months ago · newsfilecorp.com
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q3 2024. To view...